These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 10937974

  • 1. Novel approaches to retard ventricular remodeling in heart failure.
    Spinale FG.
    Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 4. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW, Verma S, Weisel RD, Li RK.
    Cardiovasc Pathol; 2005 May 02; 14(2):49-60. PubMed ID: 15780796
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 8. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG.
    J Card Fail; 2002 Dec 15; 8(6):390-8. PubMed ID: 12528092
    [Abstract] [Full Text] [Related]

  • 9. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG.
    Circ Res; 2002 Mar 22; 90(5):520-30. PubMed ID: 11909815
    [Abstract] [Full Text] [Related]

  • 10. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
    Vanhoutte D, Heymans S.
    J Mol Cell Cardiol; 2010 Mar 22; 48(3):445-53. PubMed ID: 19799912
    [Abstract] [Full Text] [Related]

  • 11. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
    Goetzenich A, Hatam N, Zernecke A, Weber C, Czarnotta T, Autschbach R, Christiansen S.
    J Heart Lung Transplant; 2009 Oct 22; 28(10):1087-93. PubMed ID: 19782292
    [Abstract] [Full Text] [Related]

  • 12. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG.
    Physiol Rev; 2007 Oct 22; 87(4):1285-342. PubMed ID: 17928585
    [Abstract] [Full Text] [Related]

  • 13. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation.
    Deschamps AM, Spinale FG.
    Cardiovasc Res; 2006 Feb 15; 69(3):666-76. PubMed ID: 16426590
    [Abstract] [Full Text] [Related]

  • 14. [Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodeling].
    Wang XM, Yang LX, Zhu SJ, Yang YJ, Guo CM, Qi F, Wei L, Shi YK, Wang Y, Ren L.
    Zhonghua Nei Ke Za Zhi; 2004 Nov 15; 43(11):828-31. PubMed ID: 15634542
    [Abstract] [Full Text] [Related]

  • 15. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.
    Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L.
    Circ Res; 1998 Mar 09; 82(4):482-95. PubMed ID: 9506709
    [Abstract] [Full Text] [Related]

  • 16. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.
    Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Böhm M.
    J Mol Cell Cardiol; 2002 Feb 09; 34(2):151-63. PubMed ID: 11851355
    [Abstract] [Full Text] [Related]

  • 17. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice.
    Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG.
    J Mol Cell Cardiol; 2000 Jan 09; 32(1):109-20. PubMed ID: 10652195
    [Abstract] [Full Text] [Related]

  • 18. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
    Am Heart J; 2005 Sep 09; 150(3):484-7. PubMed ID: 16169329
    [Abstract] [Full Text] [Related]

  • 19. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
    Janicki JS, Brower GL, Gardner JD, Forman MF, Stewart JA, Murray DB, Chancey AL.
    Cardiovasc Res; 2006 Feb 15; 69(3):657-65. PubMed ID: 16376324
    [Abstract] [Full Text] [Related]

  • 20. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
    Truter SL, Catanzaro DF, Supino PG, Gupta A, Carter J, Herrold EM, Dumlao TF, Borer JS.
    Cardiology; 2009 Feb 15; 113(3):161-8. PubMed ID: 19129699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.